Ajan Reginald

Ajan Reginald, CEO of Celixir (formerly Cell Therapy Limited) is an entrepreneur based in London, UK. Ajan Reginald is a graduate in dental surgery and masters in Biotechnology with a combinational background in science and business. A vivid hockey player, Ajan has played at international levels and is actively involved in the work of Hockey.

Ajan Reginald is currently the co-founder and the Chief Executive Officer of Celixir, which was founded by him in 2009 with Nobel Laureate Professor Sir Martin Evans. The original name of the company at the time of foundation was Cell therapy Limited.

Celixir is a private British regenerative medicine company that discovers and develops life-saving and life-altering regenerative medicines for patient’s cell and gene therapies for patients with the greatest medical need. Celixir’s unique rational design approach drives in-house discovery and has created a broad pipeline of cell and gene therapy medicines, with seven of these currently being taken forward through the development cycle.

At Celixir the pipeline is led by their investigational cardiac tissue engineered, cell therapy product, Heartcel which was designed keeping in mind to treat patients with heart failure undergoing coronary artery bypass graft (CABG) These Heartcel are injected during the bypass surgery surrounding the cardiac scar tissue in one single application. Another one of Celixir’s products is in late-stage clinical development called Tendoncel, It is for tendon repair and is currently being tested in patients who suffer from tennis elbow. In its clinical stage pipeline, Celixir is also progressing three oncology products and two further cardiac products through the pre-IND stage..